James Moy to Immunologic Deficiency Syndromes
This is a "connection" page, showing publications James Moy has written about Immunologic Deficiency Syndromes.
Connection Strength
0.861
-
Efficacy and Safety of Human Intravenous Immunoglobulin 10% (Panzyga?) in Patients with Primary Immunodeficiency Diseases: a Two-Stage, Multicenter, Prospective, Open-Label Study. J Clin Immunol. 2017 Aug; 37(6):603-612.
Score: 0.619
-
Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex? 10% Versus Gammaplex? 5% in Subjects with Primary Immunodeficiency. J Clin Immunol. 2017 Apr; 37(3):301-310.
Score: 0.151
-
Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010 Mar; 30(2):321-9.
Score: 0.091